Trial Details

Authorised
Basic Information
Clinical ID c3182
Identifier EUCTR2011-006084-22-GB
Trial Title Utilising drug levels and anti-drug antibodies to predict response to treatment in patients with Inflammatory Bowel Disease - Trough levels of anti-TNF agents in inflammatory bowel disease
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Inflammatory bowel disease MedDRA version: 14.1_Level: LLT_Classification code 10045365_Term: Ulcerative colitis_System Organ Class: 10017947 - Gastrointestinal disorders_ MedDRA version: 14.1_Level: PT_Classification code 10011401_Term: Crohn's disease_System Organ Class: 10017947 - Gastrointestinal disorders_;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Interventions Trade Name: Remicade Product Name: Infliximab Pharmaceutical Form: Infusion INN or Proposed INN: Infliximab CAS Number: 170277-31-3 Current Sponsor code: Centocor Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 10mg/kg body wt- Trade Name: Humira Product Name: adalimumab Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Adalimumab CAS Number: 331731-18-1 Current Sponsor code: EU/1/03/256/001 Concentration unit: mg milligram(s) Concentration type: not less then Concentration number: 40-mg
Participant Information
Sponsor Royal Liverpool University Hospital
City -
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement -
Study Design
Study Type Interventional clinical trial of medicinal product
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -